← Back to Search

Educational Interventions for Osteoporosis

N/A
Waitlist Available
Led By Jacques P Brown, MD
Research Sponsored by CHU de Quebec-Universite Laval
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female, aged 50 years and over
Participants must have a fragility or traumatic fracture of specific sites
Must not have
Pathological fracture
Women currently participating in a clinical trial requiring them to take a medication for osteoporosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will focus on improving evidence-based osteoporosis diagnosis and treatment for women 50 and older who have suffered a fragility fracture. It will compare the current situation to an optimal one and propose interventions to improve care. The effectiveness of these interventions will be evaluated using a randomized control design.

Who is the study for?
This trial is for women aged 50 or older who have had a fragility fracture, can understand the study information and consent form, agree to participate voluntarily, and are able to complete questionnaires over the phone. It excludes those already in a clinical trial for osteoporosis medication, unable to grasp the programme's purpose, or with fractures due to severe trauma or disease.
What is being tested?
The ROCQ programme aims to improve osteoporosis care by evaluating current diagnosis and treatment rates after fragility fractures against an ideal scenario. Interventions include educational materials and videos for patients and healthcare professionals. The effectiveness of these interventions will be measured using a randomized control design.
What are the potential side effects?
Since this trial focuses on documentation and video interventions rather than medications, traditional side effects are not expected. However, participants may experience discomfort from discussing their medical condition or changes in their management of osteoporosis.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 50 or older.
Select...
I have had a fracture due to weakness or injury at a specific site.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a fracture due to my cancer.
Select...
I am in a clinical trial for osteoporosis medication.
Select...
I have a fracture from an injury in a specific part of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: VideoExperimental Treatment1 Intervention
A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
Group II: DocumentationExperimental Treatment1 Intervention
Written educational material on osteoporosis for the participant and the physician.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Video
2008
Completed Phase 3
~4790

Find a Location

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor
171 Previous Clinical Trials
106,775 Total Patients Enrolled
1 Trials studying Osteoporosis
40 Patients Enrolled for Osteoporosis
Merck Frosst Canada Ltd.Industry Sponsor
29 Previous Clinical Trials
9,577 Total Patients Enrolled
4 Trials studying Osteoporosis
648 Patients Enrolled for Osteoporosis
AmgenIndustry Sponsor
1,433 Previous Clinical Trials
1,392,312 Total Patients Enrolled
57 Trials studying Osteoporosis
557,776 Patients Enrolled for Osteoporosis

Media Library

Documentation Clinical Trial Eligibility Overview. Trial Name: NCT00359047 — N/A
Osteoporosis Research Study Groups: Documentation, Video
Osteoporosis Clinical Trial 2023: Documentation Highlights & Side Effects. Trial Name: NCT00359047 — N/A
Documentation 2023 Treatment Timeline for Medical Study. Trial Name: NCT00359047 — N/A
~126 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top